APPLIED GENETIC TECHNOLOGIES CORPORATION

ALACHUA, FL · CIK 0001273636 · Biotech · Acquired

Recombinant adeno-associated virus (rAAV) vector expressing CNGB3 gene for treating achromatopsia by restoring cone photoreceptor function

Grants
$214K
1 award
Sector median: 1
Raised
$9.3M
2 Form D · Nov 2012
166 months since last filing
Contracts
—
No federal contracts on record
Patents
31
2 granted · 29 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$750,000
Private capital raisedForm D · SEC$8,579,358
Federal grantDepartment of Health and Human Services · Phase II · rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model$213,638
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2486Borealis Biosciences——
2487PANOME BIO INC—$12M
2488ANAVEX LIFE SCIENCES CORP.—$11M
2489APPLIED GENETIC TECHNOLOGIES CORPORATION—$9.3M
24903+2 PHARMA, LLC——
2491CELL DATA SCIENCES, INC.——
2492Cerevel Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • Kent GossettDirector
  • Edward HurwitzDirector
  • Scott KoenigDirector
  • SCOTT KOENIGDirector
  • GARHENG KONGDirector
  • NICHOLAS MUZYCZKADirector
  • Arnold OronskyDirector
  • ARNOLD ORONSKYDirector
  • James RosenDirector
  • JAMES ROSENDirector
  • FRANK TOPDirector
  • Susan WasherDirector · Executive Officer
  • SUSAN WASHERDirector · Executive Officer
  • Samuel WuDirector
  • SAM WUDirector

Patents

USPTO · 2 granted of 31
  • Triple Function Adeno-associated Virus (aav)vectors For The Treatment Of C9ORF72 Associated Diseasesapplication
  • Promoters, Expression Cassettes, Vectors, Kits, And Methods For The Treatment Of Achromatopsia And Other Diseasesapplication
  • Triple Function Adeno-associated Virus (aav)vectors For The Treatment Of C9ORF72 Associated Diseasesapplication
  • Adeno-associated Virus (aav) Systems For Treatment Of Progranulin Associated Neurodegenerative Diseases Or Disordersapplication
  • Adeno-associated Virus (aav)vectors For The Treatment Of Age-related Macular Degeneration And Other Ocular Diseases And Disordersapplication
  • Codon Optimized Nucleic Acid Encoding A Retinitis Pigmentosa Gtpase Regulator (rpgr)application
  • Promoters, Expression Cassettes, Vectors, Kits, And Methods For The Treatment Of Achromatopsia And Other Diseasesapplication
  • Promoters, Expression Cassettes, Vectors, Kits, And Methods For The Treatment Of Achromatopsia And Other Diseasesapplication
  • Promoters, Expression Cassettes, Vectors, Kits, And Methods For The Treatment Of Achromatopsia And Other Diseasesgranted
  • Recombinant Virus Production Using Mammalian Cells In Suspensiongranted
  • Adeno-associated Virus (aav)vectors For The Treatment Of Age-related Macular Degeneration And Other Ocular Diseases And Disordersapplication
  • Adeno-associated Virus (aav) Systems For Treatment Of Progranulin Associated Neurodegenerative Diseases Or Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.